Revenue for the first six months is expected to be about 20% ahead of the comparable period. Operating profit is anticipated to show high single-digit growth.
In the light of the clinical solutions' business contribution and investments made in the first half, the margin will be lower than in the comparable period, but these factors are expected to result in stronger profit growth in the second half.
